RA
SGMO

Royce & Associates’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Royce & Associates’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-69,057
Closed -$653K – 1033
2020
Q3 		$653K Buy
69,057
+3,242
+5% +$35.1K 0.01% 826
2020
Q2 		$590K Hold
65,815
– – 0.01% 844
2020
Q1 		$419K Hold
65,815
– – 0.01% 850
2019
Q4 		$551K Hold
65,815
– – ﹤0.01% 876
2019
Q3 		$596K Hold
65,815
– – 0.01% 874
2019
Q2 		$709K Hold
65,815
– – 0.01% 867
2019
Q1 		$628K Sell
65,815
-21,000
-24% -$214K 0.01% 902
2018
Q4 		$997K Sell
86,815
-54,000
-38% -$671K 0.01% 863
2018
Q3 		$2.39M Sell
140,815
-115,000
-45% -$1.75M 0.02% 795
2018
Q2 		$3.63M Buy
255,815
+71,150
+39% +$1.18M 0.03% 683
2018
Q1 		$3.51M Sell
184,665
-146,300
-44% -$3.13M 0.02% 676
2017
Q4 		$5.43M Sell
330,965
-147,500
-31% -$2.19M 0.04% 563
2017
Q3 		$7.18M Sell
478,465
-272,635
-36% -$3.01M 0.05% 469
2017
Q2 		$6.61M Hold
751,100
– – 0.04% 501
2017
Q1 		$3.91M Hold
751,100
– – 0.03% 664
2016
Q4 		$2.29M Buy
751,100
+215,000
+40% +$783K 0.01% 786
2016
Q3 		$2.48M Buy
536,100
+80,000
+18% +$407K 0.02% 747
2016
Q2 		$2.64M Hold
456,100
– – 0.02% 754
2016
Q1 		$2.76M Buy
456,100
+144,000
+46% +$865K 0.02% 761
2015
Q4 		$2.85M Buy
312,100
+100,000
+47% +$771K 0.02% 781
2015
Q3 		$1.2M Buy
+212,100
New +$1.75M 0.01% 946

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Royce & Associates's SGMO Position: Q4 2020 in Review

Royce & Associates sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2020, closing a stake of 69,057 shares — an estimated $653K sold.

Royce & Associates first reported a position in SGMO in Q3 2015 and held it in 21 quarters. The position peaked at $7.18M in Q3 2017. 223 funds tracked by Wall St. Rank hold SGMO as of Q4 2020.

  • Royce & Associates reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2020 after selling out during the quarter.
  • Royce & Associates sold 69,057 SANGAMO THERAPEUTICS INC shares in Q4 2020, an estimated $653K.
  • Royce & Associates first reported a position in SANGAMO THERAPEUTICS INC in Q3 2015 and held it in 21 quarters.
  • Royce & Associates's SANGAMO THERAPEUTICS INC position peaked at $7.18M in Q3 2017.
  • 223 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2020.

Based on Royce & Associates's 13F filing for Q4 2020, filed 8 Feb 2021.